Survey says: Brexit blues hit biopharma as industry execs overwhelmingly turn thumbs down on the UK's future
Whatever your thoughts about Brexit — for or against — the political angst that it has provoked in the UK in recent months has triggered a steady erosion in the global pharma industry’s opinion of the country as an attractive place to do research and manufacturing. And inside the UK, the daily din of controversy has provoked a clear crisis of confidence in the industry’s future.
GlobalData has been surveying a mix of pharma execs around the world each quarter this year. And after about half of their British respondents had provided a thumbs up initially, only 17% were ready to affirm that the UK will remain an attractive destination for R&D/manufacturing work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.